Transcript national drug policy - World Health Organization

NATIONAL DRUG POLICY
Access to medicines
Argentina, 2003
NATIONAL DRUG POLICY
 Prescription by generic name of drugs
Free essential drugs supply program
(REMEDIAR PROGRAM)
Priority Programs Protection: The ARV case
CONSUMPTION IMPACT ON
RETAIL PHARMACY
6.000
32%
18.555
15.000
10.000
5.000
Monthly Sales -Units (000)-
Monthly Sales -Units (000)-
5.754
24.532
25.000
20.000
85%
5.000
4.000
3.113
3.000
2.000
1.000
Ethical Market
Source: Health Ministry based on IMS Health
May 2002
May 2003
OTC market
REMEDIAR: OBJECTIVES
•To provide free essential drug to 15,000,000
poor people at every Primary Health Care
Center (PHCC) (6.000 centers)
•To strengthen the Primary Health Care
Strategy
•To promote healthy policies with social
participation
REMEDIAR: Characteristics
•The medicine kit delivered contains 48
essential drugs, covering 80% of medical
consults at PHCCs.
•Each kit has been designed to supply essential
drugs for about 300 medical consults.
•REMEDIAR stimulates domestic
pharmaceutical industry and improves quality
standards
REMEDIAR PROGRAM
FOCUS
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
71
23
6
REMEDIAR Beneficiaries
Indigent
Poor (Non indigent)
Non poor
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
84
16
REMEDIAR Beneficiaries
Without coverage
Under coverage
Source: Ministry of Health
REMEDIAR PROGRAM IS AN EQUITABLE
AND EFFICIENT ANSWER, BECAUSE:
 It guarantees the access to medicines
 It is financially sustainable
 It is technically consistent
 It is federal
 It is an adequate answer to emergency
 It promotes a lasting reform
 It allows efficient purchases
 It has a high redistributive impact
 It has a strict evaluation and monitoring mechanism
 It promotes the rational use of drugs
PRIORITY PROGRAMS
PROTECTION
The case of ARV
JOINT NEGOTIATION OF ARV
PRICES
The process has the support of Andean Health Organism
(ORAS/CONHU), World Health Organization/Pan American Health
Organization (WHO/PAHO) and UNAIDS.
Doctors Without Borders (MSF), International Red Cross and Latin
American Network of People Living with HIV/AIDS, were present as
observers.
The higher price reduction obtained was 92% and the minimum was
10%
Potential joint savings for the participating countries (10 countries),
could be around $148 US million dollars (76% of regional ARV
expenditure)
These substantial savings will annually allow that 150,000 more
people living with AIDS in the region to be assisted.
ARV PRICES NEGOTIATION OUTCOMES
(LIMA, PERU -JUNE 2003-)
Highest tritherapies cost before and after negotiation
8.000
7.694
7.000
US dollars
6.000
5.336
5.318
5.311
4.606
5.000
4.000
3.000
1.489
2.000
1.000
697
402
AZT+3TC+EFV
AZT+3TC+NVP
Before
D4T+DDI+IDV/rtv
After
D4T+DDI+LPV/rtv
NATIONAL DRUG POLICY
Access and Savings
Prescription by
generic name
3,000,000 more people
U$S 324 millions
REMEDIAR
Program
11,000,000 poor people
U$S 288 millions
Price
negotiation
4,500 more patients
U$S 6 millions